Genetics in Medicine — Progress and Pitfalls
By Editorial,
The Lancet
| 06. 06. 2015
Untitled Document
Last week, the White House decreed that human germline gene editing in biomedical research is discontinued in the USA until ethical and safety concerns are resolved. This technology involves modification of the genome in germ cells, which can then be inherited and passed on to future generations. “The administration believes that altering the human germline for clinical purposes is a line that should not be crossed at this time”, said John P Holdren, Director of the White House Office of Science and Technology Policy.
In recent years, genome engineering technology has developed the ability to edit DNA more precisely than before. The new technology is based on an enzyme complex that binds and splices DNA at precise locations, and can target a dysfunctional gene by first deleting, then repairing or replacing the target sequence with another molecule. One such technique, CRISPR/Cas—short for clustered regularly interspaced short palindromic repeats—has received attention after a study from China used the technique for the first time to edit nonviable human embryos to disable the gene for β-thalassaemia. However, the study...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...